In today’s digital-first world, our eyes are exposed to unprecedented levels of strain—from screens, artificial light, and oxidative stress. Vision concerns like age-related macular degeneration (AMD), diabetic retinopathy, and general visual decline are becoming more common as we age.
While conventional treatment options exist, many of them focus on symptom management rather than long-term eye support. The good news is emerging visual treatments such as peptide therapy can reduce visual impairments up to 80%.
The National Institutes of Health (NIH) estimates that rates of visual impairment and legal blindness in the U.S. could double by 2050. Key causes of visual impairment are:
Age-related macular degeneration (AMD)
Diabetic retinopathy
Glaucoma
Diabetic macular edema
These degenerative retinal diseases suck the enjoyment out of life. These conditions affect central vision and overall eye function.
The macula is a small part of the retina responsible for sharp central vision. It is highly sensitive to damage from:
Oxidative stress
Chronic inflammation
Age-related changes
Environmental factors like screen time and UV exposure
Macular degeneration is one of the leading causes of vision decline in adults over 50.
They key to vision health is stoping the vascular endothelial growth factor (VEGF). Vascular endothelial growth factor is a signaling protein that stimulates the growth of new blood vessels, a process called angiogenesis.
Over expression of VEGF can contribute to various diseases in the eyes like diabetic retinopathy and age-related macular degeneration.
There have been methods that may offer short-term benefits such as Aflibercept, but they often require frequent visits and may not address underlying cellular decline to prevent blindness.
The eyes contain protective barriers such as the blood-retinal barrier and blood-aqueous barrier that can make targeted support challenging. However, specific short-chain peptides may be able to interact with these barriers more effectively than traditional compounds.
This has lead to a host of research studies with peptide therapies.
Researchers hoping to solve this problem turned to the world of peptide therapy. This has lead to one of the biggest breakthroughs in eye health this century.
John Hopkins University discovered peptide therapy using AXT107 could outperform the standard of Aflibercept in reducing vascular permeability treatment but up to 86%. Continued research has shown this therapy to be an even more effective treatment.
Some key facts of the study:
Researchers tested treatments of aflibercept and AX107 along with a control of a synthetic peptide. Thirty days after treatment, vascular leakage was reduced by 86% in those treated by AXT107 and 69% of those treated with Aflibercept.
Where the specific peptides showed a more beneficial effect was after 60 days. A single treatment of AXT107 continued to suppress vascular leakage by 70% after 60 days, whereas Aflibercept was inline with the control group.
AXT107 shows huge promise to individuals with degenerative retinal diseases. The treatment is many times preference because patients are able to have less frequent clinical visits.
Peptides are short chains of amino acids that support normal biological processes throughout the body, including the eyes. In recent years, peptides have been studied for their role in:
Supporting healthy ocular tissue
Promoting normal vascular stability
Aiding in regenerative cellular processes
Their ability to interact with cellular pathways makes them an area of growing interest in the field of longevity and eye wellness.
With more time spent on screens and vision concerns on the rise, the future of eye care is shifting toward proactive, supportive approaches that focus on long-term wellness. While Peptides like AXT107 are needed for advanced conditions, a new class of peptides have emerged to help support regeneration at the cellular level: Peptide Bioregulators.
Peptide bioregulators may play an important role in this shift by encouraging healthy tissue maintenance and regeneration at the cellular level without the need for constant intervention.
Visoluten is a dietary supplement that contains natural peptides designed to support normal eye function. It works by helping to restore the natural balance of peptides in ocular tissues and may assist in maintaining:
Healthy retinal structure
Normal visual acuity
Balanced protein synthesis within eye cells
|
Feature |
Peptides |
Traditional Therapies |
|---|---|---|
|
Non-Invasive Support |
✅ Oral or topical use |
❌ Frequent injections often required |
|
Designed for Targeted Action |
✅ Cellular-level support |
❌ Broad suppression, not personalized |
|
Support for Aging Eyes |
✅ Helps maintain normal structure |
❌ Typically symptom-focused |
|
Convenient Use |
✅ Supplement format |
❌ Doctor-dependent treatments |
|
|
|
|
As scientists continue to discover different types of peptide therapy to slow vision loss. AXT107 is an incredible step towards helping solving the puzzle of retina diseases.
When people are looking for preventative maintenance for their eyes, Visoluten may be a great choice to slow age related decline.
